Agilent TechnologiesAEarnings & Financial Report
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Revenue
$1.9B
Gross Profit
$990.0M
Operating Profit
$443.0M
Net Profit
$434.0M
Gross Margin
53.2%
Operating Margin
23.8%
Net Margin
23.3%
YoY Growth
9.4%
EPS
$1.53
Agilent Technologies Q4 FY2025 Financial Summary
Agilent Technologies reported revenue of $1.9B (up 9.4% YoY) for Q4 FY2025, with a net profit of $434.0M (up 23.6% YoY) (23.3% margin). Cost of goods sold was $871.0M, operating expenses totaled $547.0M.
Key Financial Metrics
| Total Revenue | $1.9B |
|---|---|
| Net Profit | $434.0M |
| Gross Margin | 53.2% |
| Operating Margin | 23.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Agilent Technologies Q4 FY2025 revenue of $1.9B breaks down across 7 segments, led by Pharmaceuticaland Biopharmaceutical Market at $690.0M (37.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pharmaceuticaland Biopharmaceutical Market | $690.0M | 37.1% |
| Agilent Cross Lab | $290.0M | 15.6% |
| Diagnosticsand Clinical Market | $276.0M | 14.8% |
| Environmentaland Forensics Market | $180.0M | 9.7% |
| Food Market | $165.0M | 8.9% |
| Academiaand Government Market | $136.0M | 7.3% |
| Applied Markets | $102.0M | 5.5% |
Agilent Technologies Revenue by Segment — Quarterly Trend
Agilent Technologies revenue by segment across the last 4 reported quarters, showing how each business line (such as Pharmaceuticaland Biopharmaceutical Market and Agilent Cross Lab) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Pharmaceuticaland Biopharmaceutical Market | — | $690.0M | $629.0M | — |
| Agilent Cross Lab | $273.0M | $290.0M | — | $270.0M |
| Diagnosticsand Clinical Market | — | $276.0M | $258.0M | — |
| Environmentaland Forensics Market | $177.0M | $180.0M | $163.0M | $159.0M |
| Food Market | $166.0M | $165.0M | $157.0M | $147.0M |
Agilent Technologies Annual Revenue by Year
Agilent Technologies annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.9B).
| Year | Annual Revenue |
|---|---|
| 2025 | $6.9B |
| 2024 | $6.5B |
| 2023 | $6.8B |
| 2022 | $6.8B |
Agilent Technologies Quarterly Revenue & Net Profit History
Agilent Technologies results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.8B | +7.0% | $305.0M | 17.0% |
| Q4 FY2025 | $1.9B | +9.4% | $434.0M | 23.3% |
| Q3 FY2025 | $1.7B | +10.1% | $336.0M | 19.3% |
| Q2 FY2025 | $1.7B | +6.0% | $215.0M | 12.9% |
| Q1 FY2025 | $1.7B | +1.4% | $318.0M | 18.9% |
| Q4 FY2024 | $1.7B | +0.8% | $351.0M | 20.6% |
| Q3 FY2024 | $1.6B | -5.6% | $282.0M | 17.9% |
| Q2 FY2024 | $1.6B | -8.4% | $308.0M | 19.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.57B | $1.58B | $1.70B | $1.68B | $1.67B | $1.74B | $1.86B | $1.80B |
| YoY Growth | -8.4% | -5.6% | 0.8% | 1.4% | 6.0% | 10.1% | 9.4% | 7.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.86B | $11.00B | $11.85B | $11.91B | $12.16B | $12.23B | $12.73B | $12.81B |
| Liabilities | $4.64B | $5.09B | $5.95B | $5.89B | $6.02B | $5.86B | $5.99B | $5.91B |
| Equity | $6.21B | $5.90B | $5.90B | $6.03B | $6.14B | $6.37B | $6.74B | $6.91B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $333.0M | $452.0M | $481.0M | $431.0M | $221.0M | $362.0M | $545.0M | $268.0M |